Category Emerging Modalities

Lilly Bought a Dual-Payload ADC Before It Hit the Clinic. Here’s Why.

Eli Lilly acquires CrossBridge Bio and its dual-payload ADC platform before any clinical data.

Cellectar Biosciences enrolls first patient in Phase 1b of CLR 125, an iodine-125 Auger emitter targeting refractory TNBC.

Deck Bio launches a multi-target pMHC T cell engager platform that hits multiple intracellular cancer antigens with a single binder.

Cue Biopharma earns a $7.5M preclinical milestone from Boehringer Ingelheim for its CUE-501 autoimmune program.

Hemispherian doses first patients in a Phase 1/2a trial of GLIX1, a first-in-class oral TET2 activator for glioblastoma.

Immusoft presents the world's first engineered B cell therapy patient data at an FDA workshop.

AIRNA doses first patient in Phase 1 of AIR-001, an RNA-editing therapy for alpha-1 antitrypsin deficiency.

ABION shows preclinical data at AACR 2026 where its IFN-β antibody fusion ABN202 outperformed TROP2 ADCs in resistant tumors.

Renovare Therapeutics launches from stealth with up to $33.5M in ARPA-H funding for osteoarthritis regeneration.

SonoNeu exits stealth with $5.2M from a $41.3M ARPA-H program to bring sonogenetics to the clinic.